In-stent restenosis: Update on intracoronary radiotherapy

**ABSTRACT**

Stents eliminate vessel recoil and remodeling, two of the three major causes of restenosis after balloon angioplasty, but they promote the third cause, neointimal proliferation. Intracoronary radiotherapy at the time of successful repeat balloon angioplasty is proving effective in treating in-stent restenosis and lowering rates of recurrence. Current techniques and their safety and efficacy are discussed.

**KEY POINTS**

Although intracoronary radiotherapy can attenuate restenosis, it does not cure the disease.

The key is matching the irradiation to the injured area, so as not to undertreat the restenotic lesion.

To lower the risk of late thrombosis after intracoronary radiotherapy, it is recommended that clopidogrel be given for at least 6 months, and for 12 months if a new stent was placed. Aspirin is also given.

**IN THE ERA OF ROUTINE** stenting with percutaneous coronary angioplasty, in-stent restenosis remains an important limitation and is becoming an epidemic. Intracoronary radiotherapy has emerged as a promising means of reducing the risk of recurrent restenosis.

In this article, we review how intracoronary radiotherapy is performed and the major issues related to its use. We also briefly discuss other novel strategies for preventing in-stent restenosis that may redefine the role of intracoronary radiotherapy.

**THERAPEUTIC OPTIONS FOR IN-STENT RESTENOSIS**

A clear benefit of coronary stenting has been demonstrated in clinical trials. As a result, about 80% of percutaneous coronary interventions now involve stent implantation. However, in-stent restenosis remains an important problem. In the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibition in Stenting) trial, as many as 8.7% of cases required target vessel revascularization within 6 months of stent placement. If we consider that more than 700,000 percutaneous coronary procedures will be performed in the United States in 2001, based on a cost of $20,000 per case, a total of $1.2 billion will be spent this year alone to treat in-stent restenosis. In-stent restenosis has thus become an epidemic and an economic burden on society.
remodeling after percutaneous revascularization, they stimulate more neointimal proliferation than other interventional procedures.\textsuperscript{6,7} In-stent restenosis is considered an excessive healing process after tissue injury. Neointimal proliferation is now seen as the exclusive cause of in-stent restenosis,\textsuperscript{8} and antiproliferation strategies have become the focus of attempts to reduce rates of in-stent restenosis. Conventional treatments such as repeat balloon angioplasty, cutting balloon angioplasty, repeat stenting, or atherectomy have been disappointing, with recurrence rates averaging 25% to 50% for focal restenosis, and up to 65% for diffuse restenosis.\textsuperscript{9-12}

\section*{THE BASIS FOR INTRACORONARY RADIOTHERAPY}

Gamma-radiation and beta-radiation have been studied for the treatment of in-stent restenosis. Gamma-radiation, a form of electromagnetic energy carried by photons, can penetrate more than 10 mm of human tissue. Beta-radiation, carried by electrons, offers a wider range of energy and penetrates 2 to 3 mm of human tissue. In either case, the radiation can break the bonds of single-stranded DNA and cause cell death.

\begin{table}[h]
\centering
\caption{Clinical trials of intracoronary radiation for in-stent restenosis}
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{TRIAL} & \textbf{NUMBER OF PATIENTS} & \textbf{RADIATION DOSE} & \textbf{TARGET LESION} & \textbf{PRIMARY END POINTS} \\
\hline
\textbf{Gamma-radiation (iridium-192)} & & & & \\
SCRIPPS\textsuperscript{13} & 55 & 8 to 30 Gray (Gy) & Post-angioplasty stenosis (38\%) & Angiographic luminal loss at 6 months \\
Gamma-One\textsuperscript{15} & 252 & 8 to 30 Gy & In-stent restenosis, lesion length < 45 mm & Death, myocardial infarction, or target lesion revascularization at 9 months \\
WRIST\textsuperscript{14} & 100 & 15 Gy at 2.0 mm from the radiation source & In-stent restenosis, lesion length < 47 mm & Death, myocardial infarction, target lesion revascularization at 6 months \\
SVG WRIST\textsuperscript{14} & 30 & 15 Gy at 2.4 mm from the radiation source & In-stent restenosis in venous bypass grafts, lesion length < 47 mm & Death, myocardial infarction, target lesion revascularization at 6 months \\
Long WRIST\textsuperscript{16} & 120 & 15 Gy at 2.0 mm from the radiation source & Diffuse in-stent restenosis, 36 to 80 mm & Death, myocardial infarction, target lesion revascularization at 6 months \\
\hline
\textbf{Beta-radiation} & & & & \\
Beta WRIST registry & 50 & 20 Gy of yttrium-90 at 1.0 mm from the balloon-centered source wire & In-stent restenosis & Death, myocardial infarction, target lesion revascularization at 6 months \\
START\textsuperscript{21} & 476 & 16 to 20 Gy of strontium-90 or yttrium-90 at 2.0 mm from the center & In-stent restenosis at 8 months & Target vessel revascularization \\
INHIBIT\textsuperscript{22} & 332 & 20 Gy of phosphorus-32 at 1.0 mm from the center & Focal or diffuse in-stent restenosis & Death, myocardial infarction, target lesion revascularization at 9 months \\
\hline
\end{tabular}
\end{table}
and double-stranded DNA in actively dividing cells within the vascular media and intima. In this way, intracoronary radiotherapy inhibits smooth muscle proliferation, prevents arterial remodeling, and delays healing responses after vascular injury. Intracoronary radiotherapy is often also referred to as vascular brachytherapy (brachy- is Latin for “localized”).

The radioactive isotopes available for clinical use in intracoronary radiotherapy are iridium-192 for gamma-radiation, and phosphorus-32, strontium-90, yttrium-90, and rhenium-188 for beta-radiation.

### Clinical Trials of Intracoronary Radiation for In-Stent Restenosis

#### Trials of Gamma-Radiation

The efficacy of iridium-192 gamma-radiation in preventing recurrence of restenosis in patients with in-stent restenosis was established in three moderate-sized randomized, placebo-controlled trials (TABLES 1 and 2, FIGURE 1).13–15

**SCRIPPS trial.** In 1997, the SCRIPPS (Scripps Coronary Radiation to Inhibit Proliferation Post-stenting) trial13 randomized 55 patients with restenosis after angioplasty alone or angioplasty with stenting to receive gamma-radiation or placebo after successful repeat angioplasty. The late luminal loss was significantly lower in the radiation group compared with the placebo group (1.85 ± 0.89 vs 2.43 ± 0.78 mm, \( P = .02 \)).

**Gamma-One trial.** In the Gamma-One trial,15 which enrolled 252 patients, iridium-192 gamma-radiation given after successful balloon angioplasty was associated with less need for target lesion revascularization (24% vs 42%, \( P < .01 \)) and lower rates of binary angiographic restenosis (32% vs 55%, \( P = .01 \)) compared with placebo.

**WRIST.** In WRIST (Washington Radiation for In-Stent Restenosis Trial),14 the iridium-192 gamma-radiation group also had lower rates of both target lesion revascularization (23% vs 63%, \( P < .001 \)) and angiographic restenosis (19% vs 58%, \( P = .001 \)) compared with placebo at 6 months. In the subgroup of patients with in-stent restenosis within saphenous vein grafts (in SVG WRIST, gamma-radiation was also found to lower revascularization rates.14

**Long WRIST,**16 which examined long lesions (mean stent length 70 mm), reported a 50% reduction (\( P = .001 \)) in rates of target lesion revascularization.

Immediate procedural success was achieved in 100% of treated patients in all of these trials. It should be noted that many of the target lesion revascularizations in these trials were driven by repeat angiography (or angiographic restenosis) in the study protocols.

#### Trials of Beta-Radiation

Beta-radiation was initially studied as an adjunctive treatment to prevent restenosis in de novo lesions in native coronary arteries.17–19 Recently, it has also been tested as a treatment for in-stent restenosis (TABLE 1, FIGURE 1). Two randomized trials of beta-radiation for

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Follow-Up Period</th>
<th>Death, Myocardial Infarction, Target Lesion Revascularization (%)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCRIPPS13</td>
<td>12 months</td>
<td>Radiation Group 15.0, Placebo Group 48.0</td>
<td>.01</td>
</tr>
<tr>
<td></td>
<td>39 months</td>
<td>Radiation Group 23.1, Placebo Group 55.2</td>
<td>.01</td>
</tr>
<tr>
<td>Gamma-One15</td>
<td>9 months</td>
<td>Radiation Group 28.2, Placebo Group 43.8</td>
<td>.02</td>
</tr>
<tr>
<td>WRIST14</td>
<td>12 months</td>
<td>Radiation Group 35.3, Placebo Group 67.6</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Long WRIST16</td>
<td>12 months</td>
<td>Radiation Group 38.3, Placebo Group 61.7</td>
<td>.01</td>
</tr>
</tbody>
</table>

Three studies show gamma-radiation prevents recurrence of in-stent restenosis.
in-stent restenosis have been completed, but published reports are not yet available.

Waksman et al20 examined the safety and efficacy of 20.6 Gray (Gy) of yttrium-90 beta-radiation in treating in-stent restenosis20 in 50 patients, and compared the results against the placebo group in WRIST (gamma-radiation). At 6 months, the rate of target lesion revascularization was 26%, which compared favorably with the 50% reduction seen in WRIST.

START (Strontium-90 Treatment of Angiographic Restenosis Trial)21 randomized 476 patients to undergo either strontium-90 beta-radiation or placebo brachytherapy for in-stent restenosis. At 8 months, the rate of clinical restenosis was 24% in the radiation group vs 34% in the placebo group, a 34% risk reduction (P = .008). The rates of angiographic restenosis were 14% vs 42% (P < .001).

INHIBIT (Intimal Hyperplasia Inhibition with Beta In-stent Trial), a multicenter, randomized, placebo-controlled trial,22 demonstrated a 63% reduction (11% vs 29%) of recurrence of in-stent restenosis at 8 months using phosphorus-32 beta-radiation.

HOW INTRACORONARY RADIOTHERAPY IS PERFORMED

In view of the significant reduction of target lesion revascularization observed in the above trials, the US Food and Drug Administration has approved two catheter-based radiation devices for in-stent restenosis: the Beta-Cath (beta-radiation) system (Novoste, Norcross, GA) and the Checkmate (gamma-radiation) system (Cordis, Miami, FL).

Patients with recent acute myocardial infarction, poor left ventricular systolic function, presence of thrombus, or a coronary artery diameter narrower than 2.75 mm are not considered candidates for intracoronary radiotherapy.

The procedure

After completion of balloon angioplasty, intracoronary ultrasound is used to assess the diameter of the target vessel and the dose regimen for radiation therapy. Then a radiation catheter is tracked over a guidewire to the target lesion. For gamma-radiation, all catheterization personnel are cleared from the room and appropriate protective shields are put in place. A radiation oncologist inserts a ribbon that contains a predetermined dose of iridium-192 into the delivery catheter, which covers

---

**FIGURE 1.** Cumulative incidence of target lesion revascularization required after intracoronary radiotherapy using gamma-radiation (top) and beta-radiation (bottom). Percentages indicate percent reduction with therapy; all differences were statistically significant.
Intracoronary radiotherapy for in-stent restenosis

In intracoronary radiotherapy using gamma-radiation, the patient undergoes balloon angioplasty. Then a radiation catheter is tracked over a guidewire to the target lesion. A radiation oncologist inserts a ribbon with a predetermined dose of iridium-192 into the delivery catheter, to cover the target lesion. The ribbon is left in place for an average of 12 to 20 minutes ("dwell time"), depending on the vessel diameter. The angiograms below show the area of restenosis (arrows) before, during, and after gamma-radiation therapy.

In beta-radiation therapy (not shown), a radioactive source wire is advanced to the target lesion and is centered using a balloon.
the target lesion (Figure 2) plus 3 to 5 mm beyond each end. The ribbon is left in place for an average of 12 to 20 minutes ("dwell time"), depending on the vessel diameter.

In beta-radiation therapy, a radioactive source wire is delivered into a closed ("end-lumen") catheter with the aid of a centering balloon and is advanced to the target. The object is to deliver a target dose of radiation within a certain distance (typically 2 mm) from the balloon-centered source wire. The average dwell time required is 3 to 5 minutes.

### UNRESOLVED ISSUES

#### Gamma-radiation or beta-radiation?

Beta-radiation is less penetrating and, therefore, laboratory personnel do not need to leave the room (Table 3). Beta-radiotherapy requires less dwell time and, hence, shorter ischemic time compared with gamma-radiotherapy (3 to 5 minutes vs 12 to 20 minutes). However, the current beta-radiation system is limited by its larger catheter diameter and by its ability to treat only shorter target segments compared with the gamma-radiation system.

Observational studies suggest that beta-radiation and gamma-radiation have similar efficacy in the reduction of restenosis. Guiding radiation delivery with intravascular ultrasound may improve the uniformity of radiation delivery within the arterial lumen. Further studies are needed to better define the dosimetry and the role of each catheter system in the treatment of in-stent restenosis. Head-to-head trials comparing the efficacy of beta-radiation vs gamma-radiation for in-stent restenosis are underway in Europe.

#### A treatment, not a cure: recurrence of restenosis

Although intracoronary radiotherapy can attenuate restenosis, it does not cure the disease. The 3-year follow-up in the SCRIPPS trial showed that loss of luminal diameter occurred between 6 months and 3 years after intracoronary radiotherapy, suggesting that this treatment simply delays, rather than cures, restenosis.

#### Are there late complications due to radiation?

**Mitotic and aneurysmal changes.**

Although not yet reported in any clinical trials, mitotic changes (carcinoma) or aneurysmal changes in coronary arteries are a theoretically possible late sequela of intracoronary radiotherapy, and the observation of these findings may require many years of follow-up.

**Late thrombosis and myocardial infarction.**

Observed several months after intracoronary radiotherapy raised concerns about the safety of radiation. After intracoronary radiation, endothelial repair is delayed due to the same inhibiting effect of radiation on tissue proliferation and migration. Late thrombosis is

---

**TABLE 3**

### Pros and cons of gamma-radiation and beta-radiation for intracoronary radiotherapy of in-stent restenosis

<table>
<thead>
<tr>
<th></th>
<th>GAMMA-RADIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
<td>Stable radiation seed placement without constant fluoroscopic confirmation during dwell time</td>
</tr>
<tr>
<td></td>
<td>Smaller catheter diameter</td>
</tr>
<tr>
<td><strong>Disadvantages</strong></td>
<td>Deep tissue penetration</td>
</tr>
<tr>
<td></td>
<td>Long catheter dwell time, means a longer ischemic time</td>
</tr>
<tr>
<td></td>
<td>Need to clear the laboratory during dwell time</td>
</tr>
<tr>
<td></td>
<td>Extensive shielding required</td>
</tr>
<tr>
<td></td>
<td>Radiation oncologist must be present</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>BETA-RADIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
<td>Less tissue penetration</td>
</tr>
<tr>
<td></td>
<td>Less unneeded radiation to patient and health care workers</td>
</tr>
<tr>
<td></td>
<td>Shorter catheter dwell time and thus less risk from ischemia</td>
</tr>
<tr>
<td></td>
<td>Can be used with radioactive stent technology</td>
</tr>
<tr>
<td><strong>Disadvantages</strong></td>
<td>Radiation oncologist must be present</td>
</tr>
<tr>
<td></td>
<td>Intermittent fluoroscopy required during radiation delivery</td>
</tr>
<tr>
<td></td>
<td>to ensure correct positioning of radiation seeds, and hence, more radiation exposure for the operators</td>
</tr>
</tbody>
</table>

---

### Trials of beta-radiation vs gamma-radiation are underway
thought to be due to delayed re-endothelialization of stents, or to late positive arterial remodeling causing separation of the stent from the arterial wall. In the clinical trials, radiotherapy reduced the need for target lesion revascularization—but not the rates of myocardial infarction or death. In fact, Gamma-One, the largest trial of gamma-radiotherapy for in-stent restenosis, showed a trend of increased death (3.1% vs 0.8%, \( P = .17 \)) and myocardial infarction (4.6% vs 2.5%, \( P = .09 \)) in the iridium-192 group vs the placebo group at 9 months. In the pooled analysis of the brachytherapy trials, late thrombosis was reported in 9.1% of the radiotherapy group vs 1.2% of the placebo group (\( P < .0001 \)) at a median of 5 months; acute myocardial infarction was reported in 43% of these patients. By multivariate logistic regression analysis, new stent implantation and long lesions were found to be the major predictors of late thrombosis.

The Plavix WRIST registry reported the efficacy of a 6-month course of clopidogrel (Plavix) and aspirin in preventing subacute thrombosis after iridium-192 radiotherapy. In beta-radiotherapy trials, prolonged clopidogrel and aspirin therapy (3 to 6 months) was associated with a low incidence of late thrombosis (0% to 2% reported at 6 to 8 months of angiographic follow-up).

**Should we use intracoronary radiotherapy at the time of original stent placement?**

Neither current catheter delivery system is approved for the primary prevention of restenosis, ie, use at the time of angioplasty of de novo lesions. A litineh some studies have demonstrated the efficacy of this therapeutic option, uncertainty about the long-term effects of radiation limits its broader application at this time.

**FUTURE TREATMENT OPTIONS FOR IN-STENT RESTENOSIS**

Parallel to the development of catheter-based intracoronary radiotherapy has been the investigation of beta-radioactive stents—ie, stents coated with phosphorus. A potential advantage of radioactive stents that emit beta-radiation is that they do not require a radiation oncologist or additional shielding in the catheterization laboratory.

Although radioactive stents essentially eliminate in-stent restenosis, stent-edge hyperplasia due to a stimulating effect of low-dose radiation (“geographic miss”) and to balloon injury is a major limitation of this technique. Further research should focus on improving stent dose, distribution, isotope, and stent design (eg, square-shouldered balloons, cold-end stents). A balloon catheter filled with beta-emitting rhenium-188 has been shown as feasible in pilot studies. Given that neointimal hyperplasia constitutes the major mechanism for in-stent restenosis, antiproliferative drugs such as sirolimus (Rapamycin), paclitaxel (Taxol), and tranilast are plausible options for this “disease.” Drug-eluting stents may enhance local delivery of these drugs and are undergoing phase III trials to explore their efficacy in eliminating in-stent restenosis. If drug-eluting stents prove effective in inhibiting neointimal hyperplasia, a revision of the indications for intracoronary radiotherapy may be necessary.

**REFERENCES**


ADDRESS: David J. Moliterno, MD, Department of Cardiology, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, OH 44195; e-mail molited@ccf.org.